Carcinogenicity and mutagenicity testing, then and now1I dedicate this paper to the memory of Ernst L. Wynder, MD, Founder and President of the American Health Foundation, a specialized research center on the causes, modulators and prevention of the main chronic diseases, with emphasis on cancer prevention. Ernst Wynder died on July 14, 1999.1

Autor: John H. Weisburger
Rok vydání: 1999
Předmět:
Zdroj: Mutation Research/Reviews in Mutation Research. 437:105-112
ISSN: 1383-5742
DOI: 10.1016/s1383-5742(99)00077-0
Popis: Cancer is a dread disease worldwide. Mortality of individuals suffering from cancer is high, despite the current improved methods of precocious detection, surgery and therapy. Prevention of cancer is the recognized goal of many activities in cancer research. This aim was recognized early to involve the bioassay of environmental chemicals or mixtures. The first such study involved application of coal tar to the ear of rabbits, and later on to the skin of mice. Subsequently, laboratory rats were introduced, and hamsters were utilized as a substitute for the unwieldy tests in rabbits. Investigators also became concerned with the mechanisms of carcinogenesis, and more definitive approaches to carcinogen bioassay in laboratory animals, as possible indicators of cancer risk in humans. These tests were expensive and lengthy, and did not serve the important purpose of accurately measuring risk of cancer to humans. Once it was realized that DNA and the genetic apparatus might be a key target, rapid bioassays in bacterial and mammalian cell systems were introduced successfully. Thus, batteries of tests are now available to detect effectively human cancer risks, and provide novel approaches to determine the underlying mechanisms, as a sound basis for cancer prevention.
Databáze: OpenAIRE